Analyzing heterogeneity in Alzheimer Disease using multimodal normative modeling on imaging-based ATN biomarkers
Authors:
Sayantan Kumar,
Tom Earnest,
Braden Yang,
Deydeep Kothapalli,
Andrew J. Aschenbrenner,
Jason Hassenstab,
Chengie Xiong,
Beau Ances,
John Morris,
Tammie L. S. Benzinger,
Brian A. Gordon,
Philip Payne,
Aristeidis Sotiras
Abstract:
INTRODUCTION: Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer Disease (AD) heterogeneity. We employed a deep learning-based multimodal normative framework to analyze individual-level variation across ATN (amyloid-tau-neurodegeneration) imaging biomarkers.
METHODS: We selected cross-sectional discovery (n = 665) and replication cohorts (…
▽ More
INTRODUCTION: Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer Disease (AD) heterogeneity. We employed a deep learning-based multimodal normative framework to analyze individual-level variation across ATN (amyloid-tau-neurodegeneration) imaging biomarkers.
METHODS: We selected cross-sectional discovery (n = 665) and replication cohorts (n = 430) with available T1-weighted MRI, amyloid and tau PET. Normative modeling estimated individual-level abnormal deviations in amyloid-positive individuals compared to amyloid-negative controls. Regional abnormality patterns were mapped at different clinical group levels to assess intra-group heterogeneity. An individual-level disease severity index (DSI) was calculated using both the spatial extent and magnitude of abnormal deviations across ATN.
RESULTS: Greater intra-group heterogeneity in ATN abnormality patterns was observed in more severe clinical stages of AD. Higher DSI was associated with worse cognitive function and increased risk of disease progression.
DISCUSSION: Subject-specific abnormality maps across ATN reveal the heterogeneous impact of AD on the brain.
△ Less
Submitted 1 July, 2024; v1 submitted 4 April, 2024;
originally announced April 2024.
